探讨中性粒细胞与淋巴细胞比值(NLR)诊断子宫内膜异位症(EMs)的临床意义。

选取2006年1月至2010年12月于本院经组织病理学检查确诊并行手术治疗的90例EMs患者为研究对象，纳入EMs组(n＝90)，再进一步按照美国生育协会修正标准分期(r－AFS)对EMs进行分期，并分别纳入≤Ⅱ期亚组(n＝36)和≥Ⅲ期亚组(n＝54)。选取同期于本院经组织病理学检查确诊并手术治疗的卵巢良性肿瘤患者纳入卵巢良性肿瘤组(n＝60)，选取同期于本院进行健康体检且近3个月无感染性疾病史的健康妇女纳入对照组(n＝60)。分别采集3组受试者的空腹肘静脉血，测定CA₁₂₅及中性粒细胞与淋巴细胞水平，并计算NLR值(本研究遵循的程序符合本院人体试验委员会所制定的伦理学标准，得到该委员会批准，分组征得受试对象本人的知情同意，并与之签署临床研究知情同意书)。

EMs组NLR值、CA₁₂₅水平明显高于卵巢良性肿瘤组和对照组，且差异均有统计学意义(P<0.05)。EMs组中，≤Ⅱ期亚组与≥Ⅲ期亚组的CA₁₂₅水平和阳性率分别比较，差异均有统计学意义(P＝0.001，P＝0.000)，NLR值和阳性率比较，差异无统计学意义(P>0.05)。

NLR是一种新的炎症评价指标，对EMs的初筛、早期诊断具有一定价值。

To explore the clinical value of neutrophil-to-lymphocyte ratio (NLR) in endometriosis(EMs).

From January 2006 to December 2010, 90 patients with EMs, 60 patients with benign ovarian tumors, 60 healthy women were included in the study. They were divided into EMs group[n=90, with ≤stageⅡsubgroup(n=36)and ≥ stage Ⅲ subgroup(n=54)], benign ovarian tumors group(n=60)and control group(n=60). NLR value and serum CA₁₂₅ level were measured and calculated. The study protocol was approved by the Ethical Review Board of Investigation in Human Being of Chaohu First Hospital. Informed consent was obtained from each patients.

The NLR value and CA₁₂₅ level in EMs group were significantly higher than those in benign ovarian tumor group and control group, respectively (P<0.05). There had significant differences of CA₁₂₅ level and the positive rate between ≤stageⅡsubgroup and ≥ stage Ⅲ subgroup in EMs group. And there had no significant difference in NLR value and the positive rate between two subgroups.

NLR value is a new inflammatory target, which has a good value on EMs primary screening and early diagnosis.